Zacks Research Issues Positive Forecast for NTLA Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a report released on Tuesday, January 28th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($1.40) for the quarter, up from their prior forecast of ($1.43). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. Zacks Research also issued estimates for Intellia Therapeutics’ Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.94) EPS, FY2025 earnings at ($6.20) EPS, Q1 2026 earnings at ($1.38) EPS, Q2 2026 earnings at ($1.26) EPS, Q3 2026 earnings at ($1.51) EPS, Q4 2026 earnings at ($2.44) EPS and FY2026 earnings at ($6.59) EPS.

Other equities research analysts have also recently issued research reports about the stock. Chardan Capital raised their price objective on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. Wedbush reissued a “neutral” rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Oppenheimer dropped their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Finally, William Blair reissued a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.71.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $10.32 on Friday. The company’s fifty day moving average price is $12.26 and its 200-day moving average price is $17.62. The firm has a market capitalization of $1.05 billion, a P/E ratio of -1.90 and a beta of 1.83. Intellia Therapeutics has a 1-year low of $9.25 and a 1-year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The company’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period last year, the firm earned ($1.38) EPS.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 29,000 shares of company stock worth $352,551 in the last quarter. Company insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. Eastern Bank acquired a new position in shares of Intellia Therapeutics in the third quarter valued at approximately $41,000. Values First Advisors Inc. acquired a new position in shares of Intellia Therapeutics in the third quarter worth $54,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares during the period. KBC Group NV raised its stake in shares of Intellia Therapeutics by 37.3% in the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after acquiring an additional 1,020 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Intellia Therapeutics by 182.7% in the third quarter. Blue Trust Inc. now owns 4,189 shares of the company’s stock valued at $94,000 after purchasing an additional 2,707 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.